Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amyotrophic lateral sclerosis

Active Lifestyle With Moderate Exercise May Reduce Risk Of ALS In Men: Study

Maintaining an active lifestyle with moderate physical activity and fitness may reduce the risk of amyotrophic lateral sclerosis (ALS) in men, the study revealed.

Medical Daily

Amylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024

Amylyx missed Wall Street's expectations on Thursday amid struggles for its amyotrophic lateral sclerosis drug, and AMLX stock crashed.

Investors Business Daily

Terminally ill mum wants ‘happy memories’ with family after hand numbness turned out to be deadly disease

Charlotte Parker, 28, was diagnosed with amyotrophic lateral sclerosis (ALS) nine months after giving birth.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Parkinson’s Drug Shows Promise In Delaying Symptoms Of ALS

Amyotrophic lateral sclerosis is an incurable disease that causes people to gradually lose control of their muscles.

Zenger

Hockey great Salming succumbed unusually quick to ALS, doctor says

Toronto Maple Leafs great Borje Salming, who passed away on Thursday from nervous disease amyotrophic lateral sclerosis (ALS), succumbed unusually quickly to the disease less than four months after diagnosis, his doctor told Swedish broadcaster SVT.

Reuters

Controversial ALS drug from Amylyx gets rare second FDA meeting

Amylyx Pharmaceuticals Inc.’s controversial treatment for amyotrophic lateral sclerosis won the support of a panel of U.S. regulatory advisers, putting the product on track for likely clearance.

Tribune News Service

ALS patient sets up foundation for united front against disease

Ichiro Hatanaka, a former employee of the Japan External Trade Organization (JETRO), who was told he had a limited life expectancy after being diagnosed with ALS (amyotrophic lateral sclerosis), has established a foundation to support others fighting the disease.

The Japan News/Yomiuri

Read news from The Economist, FT, and more,
with one subscription

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

NeuroSense Shares Surge On Encouraging Data From Alzheimer's-Associated Biomarker Study

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD). Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating PrimeC. Preliminary results showed that levels of disease-related biomarkers in people with ALS were unchanged, in contrast…

Benzinga

EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition

Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory disorders.

Benzinga

Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candidate

Stealth BioTherapeutics (NASDAQ: MITO) presented Pre-Clinical clinical results of SBT-272 for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at the Keystone Neurodegeneration Symposium in Keystone, held June 5-9, 2022.

Benzinga

Why Stealth BioTherapeutics Shares Are Surging Today?

Stealth BioTherapeutics Corp (NASDAQ:MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium. A Phase 1 study to evaluate the safety and tolerability…

Benzinga

Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate

The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035 with regard to the treatment of patients with amyotrophic lateral sclerosis (ALS).

Benzinga

Voyager Therapeutics' TRACER Capsids Show Encouraging Action In Animal Models

Voyager Therapeutics Inc (NASDAQ:VYGR) will present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction at the American Society of Gene and Cell Therapy Annual Meeting. Voyager's TRACER capsid discovery platform has identified a novel AAV9-derived capsid, VCAP-102, which demonstrated 50-fold better transduction in mice and…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Organisations

Medicines and Healthcare products Regulatory Agency

23 stories

Amylyx Pharmaceuticals

20 stories

BridgeBio Pharma

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Amyotrophic lateral sclerosis

14 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.